Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding " Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2-advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.

被引：0
|
作者：
Sherry, A. D. [1 ]
Lin, T. A. [2 ]
McCaw, Z. R. [3 ,4 ]
Ludmir, E. B. [5 ,6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Div Radiat Oncol, Houston, TX USA
[2] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[3] Insitro, South San Francisco, CA USA
[4] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA
[5] Univ Texas MD Anderson Canc, Dept Gastrointestinal Radiat Oncol, Div Radiat Oncol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2024.05.543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：747 / 748
页数：2
相关论文
共 14 条
  • [11] Abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitor in participants with HR+, HER2-breast cancer - A pooled analysis of the endocrine therapy-naive participants with measurable disease in MONARCH 2 and MONARCH 3
    Goetz, Matthew P.
    Trujillo, Jose Luis Gonzalez
    Toi, Masakazu
    Huober, Jens
    Llombart-Cussac, Antonio
    Zhang, Wei
    Knoderer, Holly
    Haddad, Nadine
    Van Hal, Gertjan
    Sledge, George W., Jr.
    CANCER RESEARCH, 2022, 82 (04)
  • [12] Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR-positive (HR+), HER2-negative (HER2-) advanced breast cancer
    Goetz, M. P.
    Johnston, S.
    Martin, M.
    Tokunaga, E.
    Park, I. H.
    Huober, J.
    Toi, M.
    Price, G. L.
    Boye, M.
    Li, L.
    Forrester, T.
    Gainford, C.
    Gable, J.
    Carter, G. C.
    Sood, A.
    Dileo, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 288 - 289
  • [13] Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials
    Fasching, P. A.
    Harbeck, N.
    Jerusalem, G.
    Colleoni, M. A.
    Neven, P.
    Franke, F.
    De laurentiis, M.
    Tripathy, D.
    Martin, M.
    Babu, G.
    Yardley, D.
    Wheatley-Price, P.
    Chan, A.
    Vazquez, R. Villanueva
    Nusch, A.
    Gu, E.
    Hu, H.
    Pathak, P.
    Thuerigen, A.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S460 - S460
  • [14] Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)
    Neven, P.
    Fasching, P. A.
    Chia, S.
    Jerusalem, G.
    De laurentiis, M.
    Im, S. -A.
    Petrakova, K.
    Bianchi, G. V.
    Martin Jimenez, M.
    Nusch, A.
    Sonke, G. S.
    de la Cruz Merino, L.
    Beck, J. T.
    Zarate, J. P.
    Wang, Y.
    Chakravartty, A.
    Wang, C.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S194 - S194
12